Dongcheng Pharmaceutical (002675.SZ): 225Ac-LNC1011 injection approved for clinical trials

Zhixun Finance App News, Dongcheng Pharmaceutical (002675.SZ) announced that its holding subsidiary, Yantai Lanna Cheng Biotechnology Co., Ltd. (referred to as "Lanna Cheng"), has received the drug clinical trial approval notification for 225Ac-LNC1011 injection issued by the China National Medical Products Administration. The company will soon carry out clinical trials for prostate cancer.